Biotechnology News

Cutting edge news about companies engaged in the research and development of new drugs, medical devices and procedures as well as research, books and information on FDA approvals, patents and awards. Biotechnology news highlights the use of biological processes, organisms or systems to manufacture products that improve the quality of life.

Huntington Study Group Launches Project AWARE 2.0 Observational Study

Huntington Study Group Launches Project AWARE 2.0 Observational Study

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024 - Huntington Study Group

FuseBio Presents New Data at AACR: Targeting a Functionally-Selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-Tumor Activity

FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells. - April 09, 2024 - Fuse Biotherapeutics

Ngram Expands AI Dataset Offerings with Descriptive Question Answering for Healthcare

Ngram Expands AI Dataset Offerings with Descriptive Question Answering for Healthcare

New open-source medchat-qa-descriptive dataset enables AI models to provide comprehensive answers to complex medical queries. - March 22, 2024 - ngram Inc.

Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology

The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an... - March 20, 2024 - Parvus Therapeutics U.S., Inc.

Bench International Adds Industry Veteran Dr. Renee P. Tannenbaum to Executive Leadership Team

Bench International Adds Industry Veteran Dr. Renee P. Tannenbaum to Executive Leadership Team

Tannebaum Brings Deep Industry Experience in Pharma and Biotech and Board Expertise to Meet Evolving Life Sciences Talent Demands - March 19, 2024 - Bench International

MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq

MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq

MENADNA Inc., has entered into an exclusive partnership with ProPhase Labs' subsidiary, Nebula Genomics, aiming to advance genomic testing in Jordan, Oman, and Iraq. This collaboration will leverage Nebula Genomics' advanced sequencing technologies and MENADNA's bioinformatics capabilities to improve the quality and relevance of genomic data in these historically underserved regions. - March 18, 2024 - MENADNA

Sabina Ewing Awarded Bench and Deloitte Inaugural Life Sciences  Tech Innovation Award

Sabina Ewing Awarded Bench and Deloitte Inaugural Life Sciences Tech Innovation Award

Award Recognizes Exceptional Contributions by Women in the Life Sciences Industry - March 15, 2024 - Bench International

Creative Biolabs: Illuminate Neurological Disease Research and Therapy Development with Customized Animal Models

Creative Biolabs is proud to announce its new-year resolution to dive deeper into sourcing professional animal model solutions for neurological disorder studies. - March 15, 2024 - Creative Biolabs

Eminent Spine's 3D Titanium Anterior Lumbar Stand-Alone System Usage Report and Clinical Study

Eminent Spine's 3D Titanium Anterior Lumbar Stand-Alone System Usage Report and Clinical Study

Eminent Spine's 3D Titanium ALIF Stand-Alone System received FDA 510(K) clearance in October 2022 and has reported 102 total implants and 273 screws used in operations. - March 14, 2024 - Eminent Spine

Innovation in Healthcare: Medical Websites Vie for Coveted Best Medical Website WebAward

Innovation in Healthcare: Medical Websites Vie for Coveted Best Medical Website WebAward

The Web Marketing Association is looking for the best medical websites in the world as part of their 28th annual international WebAward Competition for Web site development at www.webaward.org. The WebAwards is the standards-defining competition that sets benchmarks for 90 industries, including healthcare, healthcare provider, medical, medical equipment, biotechnology and pharmaceutical websites. - March 13, 2024 - Web Marketing Association

DNA Data Storage Alliance Releases Its First Specifications for Storage of Digital Data in DNA

DNA Data Storage Alliance Releases Its First Specifications for Storage of Digital Data in DNA

Specifications define recommended methods for storing basic vendor and CODEC information within a DNA data storage archive. - March 12, 2024 - DNA Data Storage Alliance

M4 Engineering Inc. Announces the Opening of Midwest Technical Center

M4 Engineering Inc. Announces the Opening of Midwest Technical Center

M4 Engineering Inc., a leading Engineering firm in conceptual design, analysis, and prototype development is happy to announce that it has opened an office in Shakopee, MN. This office aims to leverage M4’s extensive experience in Aerospace and advanced materials and assist commercial companies, startups, and government agencies in driving innovation and pushing technology envelopes. - February 29, 2024 - M4 Engineering

ALS TDI Launches ALS Trial Navigator: A Revolutionary Platform to Simplify Access to Clinical Trials

ALS TDI Launches ALS Trial Navigator: A Revolutionary Platform to Simplify Access to Clinical Trials

The ALS Therapy Development Insitute (ALS TDI) has announced the beta launch of the ALS Trial Navigator. This innovative set of tools is designed to guide people with ALS and caregivers through the process of finding and understanding ALS clinical trials – with the ultimate goal of personalizing the search process and helping users make informed decisions about participation in trials. - February 29, 2024 - ALS Therapy Development Institute

Creative Biolabs Supplies Recombinant Antibodies for Pharmaceutical Breakthroughs

Creative Biolabs reaffirmed its dedication to supplying high-quality antibody reagents in 2024. - February 28, 2024 - Creative Biolabs

Gotham Biotech’s Histoplasma Urinary Antigen EIA Kit Now Available for Purchase as Histoplasma Spreads in the U.S.

Gotham Biotech’s Histoplasma Urinary Antigen EIA Kit Now Available for Purchase as Histoplasma Spreads in the U.S.

Histoplasmosis is a systemic disease caused by the thermally dimorphic fungus Histoplasma capsulatum. H. capsulatum is distributed worldwide and endemic to the Ohio and Mississippi River Valleys, where the CDC estimates 60% to 90% of people who live in the region have been exposed to the fungus at some point during their life, and to certain regions of Central and South America. Medicare records from 2007 to 2016 have found cases of histoplasmosis have now spread to 47 states and Washington, DC. - February 15, 2024 - Gotham Biotech

Bench International and Deloitte Launch the "Bench and Deloitte Life Sciences Tech Innovation Award" to Celebrate Outstanding Women in Life Sciences

Bench International and Deloitte Launch the "Bench and Deloitte Life Sciences Tech Innovation Award" to Celebrate Outstanding Women in Life Sciences

First-ever award to be presented on March 14, during LAMedTechWeek, at BioscienceLA. - February 13, 2024 - Bench International

Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report

Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC

WorldUpstart Launches Next U.S. Market Gateway Accelerator with 11 Impressive International MedTech and Life Science Companies

WorldUpstart Launches Next U.S. Market Gateway Accelerator with 11 Impressive International MedTech and Life Science Companies

WorldUpstart launched the Winter 2024 U.S. Market Accelerator with eleven international Life Science and MedTech companies poised for growth. Given that only 20% of international companies typically succeed upon their initial entry into the U.S. market, the success rate of WorldUpstart’s accelerator program participants stands out at 40%. The program more than doubles the participant’s chances, creating a paradigm shift in their market entry strategy. - February 08, 2024 - WorldUpstart

RX Global's INTERPHEX Puts Hot-Topic Science in 2024 Event

INTERPHEX, the premier pharmaceutical and biotechnology event taking place April 16-18, 2024 showcases innovation and critical discussions across the entire pharmaceutical product development lifecycle. - February 08, 2024 - RX

CloudLIMS Demonstrates Advances in Its LIMS for Clinical and Analytical Labs at Pittcon 2024

CloudLIMS demonstrates advances in its secure, configurable LIMS for clinical & analytical testing labs at booth 1905 at Pittcon 2024 from February 26-28, 2024. - February 08, 2024 - CloudLIMS

Flow Circuits and Rapid Fluidics Ltd. Announce Partnership to Drive Microfluidic Innovation

Flow Circuits design platform and Rapid Fluidics 3D Print capabilities perfectly complement each other for rapid fluidic system development. Combined they empower researchers in diverse markets such as Pharmaceutical & Life Sciences Research, Point of Care Testing and Clinical Diagnostics, and Environment and Industrial Analytics. - February 05, 2024 - Rapid Fluidics Ltd

Accelerating Drug Discovery: Life Science and IT Leaders Explore the Power of Artificial Intelligence April 15-17 in Boston

AI to Take Center Stage at Bio-IT World Conference & Expo, the Hub for Pharmaceutical, Biotech and IT Collaboration - February 04, 2024 - Cambridge Healthtech Institute

Creative Diagnostics Launches Serum Plate Agglutination Test for In Vitro Detection of Multiple Pathogens

Creative Diagnostics is pleased to announce the launch of its Serum Plate Agglutination Test. - February 04, 2024 - Creative Diagnostics

Creative Diagnostics Launches Aflatoxin Test Reagents to Ensure Food Safety

Creative Diagnostics has announced the launch of Aflatoxin Test Reagents to detect harmful mycotoxins in various food products. - February 04, 2024 - Creative Diagnostics

vermicon AG Launches the First Test Kits for Rapid & Specific Enumeration of Bacterial Species in Multi-Species Probiotics

vermicon AG announces the launch of the first Flow VIT® test kits for the probiotics sector: Flow VIT® Lactobacillus rhamnosus, Flow VIT® Bifidobacterium lactis, Flow VIT® Lactobacillus plantarum and Flow VIT® Bifidobacterium longum. These state-of-the-art kits enable rapid and specific enumeration of bacterial cells, even in complex mixtures, and represent a significant leap forward in precision and efficiency for quality control of probiotics. - February 02, 2024 - vermicon AG

Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials Report

New Market Research Shows Different Patient Preferences for Electronic Diaries - January 31, 2024 - Life Science Strategy Group, LLC

Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research

Creative Diagnostics has announced P53 and TP53 antibodies and solutions to support cancer research. - January 26, 2024 - Creative Diagnostics

First Patient Enrolled In Thrombolex’s RESCUE II Study – On-Table Pharmacomechanical Lysis Without Post-Procedural Infusion

First Patient Enrolled In Thrombolex’s RESCUE II Study – On-Table Pharmacomechanical Lysis Without Post-Procedural Infusion

Thrombolex, Inc. announced the enrollment of the first patient in the RESCUE II study using the BASHIR™ Endovascular Catheter for the treatment of acute intermediate-risk pulmonary embolism by Drs. Riyaz Bashir and Vladimir Lakhter, at Temple University Hospital, Philadelphia, Pennsylvania. - January 22, 2024 - Thrombolex, Inc.

Huntington Study Group Announces 2024 Annual Meeting

Huntington Study Group Announces 2024 Annual Meeting

The Huntington Study Group® (HSG), together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), is pleased to announce that its annual meeting for 2024 is slated to take place from November 6-9 at the... - January 22, 2024 - Huntington Study Group

Impact of the In Vitro Diagnostic Regulation on Clinical Trials in the EU and CRO Outsourcing Report

IVDR Delays Driving Trial Sponsors to Actively Seek Alternative Site and CRO Outsourcing Strategies - January 17, 2024 - Life Science Strategy Group, LLC

NuvOx Pharma Announces Issuance of a New Patent

NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.” - January 14, 2024 - NuvOx Therapeutics

Thrombolex, Inc. Announces the New Bashir™ .035 Endovascular Catheters

Thrombolex, Inc. Announces the New Bashir™ .035 Endovascular Catheters

Thrombolex, Inc., announces an expansion of the existing product line with the new BASHIR™ .035 and BASHIR™ S-B .035 Endovascular Catheters, which are comparable with an 0.035” guidewire. The BASHIR™ and BASHIR™ S-B Endovascular Catheters are 510(k) cleared for the treatment of acute pulmonary embolism (PE). - January 09, 2024 - Thrombolex, Inc.

Bench International Enters Into Ground Breaking Strategic Alliance with Ashton Tweed

Bench International Enters Into Ground Breaking Strategic Alliance with Ashton Tweed

First of Its Kind Alliance Extends Mutual Service Offerings to Better Serve Clients - January 03, 2024 - Bench International

Huntington Study Group and Roche Collaborate on GENERATION HD2 Study

Huntington Study Group and Roche Collaborate on GENERATION HD2 Study

The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc. (HSGCR), is pleased to announce a collaboration with Roche-Genentech to optimize our collective experiences in Huntington’s disease (HD) clinical research. Together we are... - December 13, 2023 - Huntington Study Group

Creative Diagnostics Launches Macrophage Migration Inhibitory Factor Reagents for Research Applications

Creative Diagnostics has launched a portfolio of Macrophage Migration Inhibitory Factor (MIF) reagents for researchers. - December 13, 2023 - Creative Diagnostics

Creative Diagnostics Announces New Test Reagents for Dapsone

Creative Diagnostics has announced the launch of a range of new reagents for the analysis of Dapsone in food. - December 13, 2023 - Creative Diagnostics

Microvascular Therapeutics Selected as a Participant in the 2023 H7 BioCapital Accelerator Program

Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has been selected to join the prestigious H7 Healthcare Accelerator 2023 Cohort, powered by H7 BioCapital. The program is renowned for providing a dynamic platform... - December 13, 2023 - Microvascular Therapeutics, Inc.

Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction

Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and... - December 13, 2023 - Microvascular Therapeutics, Inc.

Booth Unveiling Soon: Creative Biolabs and Ingenious Antibody Products at AET US 2023

Creative Biolabs highlights its participation in the upcoming Antibody Engineering and Therapeutics US 2023 conference, taking place from December 13–16, 2023. The event will be held in San Diego. - December 07, 2023 - Creative Biolabs

QuBind.com Makes Major Strides in T-Cell Immunotherapy with Revolutionary AI Innovation

In just 18 months, the young startup QuBind.com has achieved a remarkable breakthrough in T-cell immunotherapy, developing an advanced AI stack that is set to revolutionize personalized medicine. This significant milestone, reached with predominantly bootstrap funding, support from friends, family, and a strategic investment from a handful general partners in the PE sector, underscores the company's innovative spirit and scientific prowess. - December 05, 2023 - QuBind Technologies Corp

San Juan Regional Medical Center Introduces Endolumik’s Novel Fluorescent Device to New Mexico

San Juan Regional Medical Center Introduces Endolumik’s Novel Fluorescent Device to New Mexico

Endolumik introduces the FDA-approved Gastric Calibration Tube at San Juan Regional Medical Center for New Mexico's first fluorescent-guided bariatric surgery. Dr. Philip Ernest praises its pivotal role in improving safety and visualization in robotic procedures, aligning with the hospital's tech-driven safety initiatives. Invented by Dr. Nova Szoka, the device addresses safety and performance concerns, reflecting a collaborative push to expand access to advanced bariatric solutions. - November 27, 2023 - Endolumik, Inc.

Marianne K. Henderson, MS PMP, Senior Advisor at the U.S. National Cancer Institute, NIH, Joins CloudLIMS’ Scientific Advisory Board

CloudLIMS is pleased to announce that Marianne K. Henderson, MS PMP, Senior Advisor at the U.S. National Cancer Institute, NIH, has joined CloudLIMS’ Scientific Advisory Board (SAB). - November 17, 2023 - CloudLIMS

Announcing the Recipients of the 2024 Wisconsin Titan 100

Titan CEO and headline sponsor Wipfli LLP are pleased to announce Ms. Ayla Annac, CEO/President of InvivoSciences, Inc. as a 2024 Wisconsin Titan 100. The Titan 100 program recognizes Wisconsin’s Top 100 CEO’s & C-level executives. They are the area’s most accomplished... - November 08, 2023 - InvivoSciences

Creative Diagnostics Launches Carbamazepine Test Reagents

Creative Diagnostics has announced the release of its new line of Carbamazepine Test Reagents. - November 04, 2023 - Creative Diagnostics

Creative Diagnostics Announces New CLDN6 Solutions for Cancer Research

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has launched a range of antibodies, antigens and kits against CLDN6 to support researchers worldwide in preclinical and clinical safety/efficacy testing. CLDN6 may be involved in the development and... - November 04, 2023 - Creative Diagnostics

Creative Biolabs Unveils ADC Services, Igniting Excitement in the Biotech Industry

Creative Biolabs, a prominent provider of groundbreaking biotechnology solutions, proudly announced the expansion of its antibody-drug conjugate (ADC) business with the introduction of novel services. In response to the escalating demand for precision therapies, ADCs have emerged as a promising... - October 29, 2023 - Creative Biolabs

Thrombolex Announces Significant New Insights from the RESCUE Trial with the BASHIR™ Endovascular Catheter

Thrombolex Announces Significant New Insights from the RESCUE Trial with the BASHIR™ Endovascular Catheter

Thrombolex, Inc., announced never-before-reported major reductions in obstruction in all of the segmental pulmonary arteries (PA), based on independent core lab data analysis of 107 patients from 18 sites in the USA, with acute intermediate-risk pulmonary embolism (PE), using the BASHIR™ Endovascular Catheter and small doses of tPA. The RESCUE trial also showed unsurpassed efficacy and safety in this patient population compared to recently published studies with other FDA-cleared devices. - October 24, 2023 - Thrombolex, Inc.

Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory®  Platform Reaches the Unreachable

Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory® Platform Reaches the Unreachable

The Huntington Study Group® (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc. (HSGCR), a world leader in conducting clinical trials for Huntington’s disease (HD), today announces that the pilot observational study on their innovative online direct-to-patient... - October 16, 2023 - Huntington Study Group

Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development

Creative Diagnostics has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of NALFIA. - October 15, 2023 - Creative Diagnostics

NuvOx Therapeutics Wins Most Fundable Company by Pepperdine Graziadio Business School

NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the Pepperdine Graziadio Business School's sixth annual Most Fundable Companies® List. NuvOx Therapeutics competed against over 3,000 of early-stage US companies to be named one of 17 companies in total. - October 11, 2023 - NuvOx Therapeutics

Press Releases 51 - 100 of 2,253